# Alexza Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alexza-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Mountain View, US
- Website: www.alexza.com
- Total disclosed funding: $92M
- Latest round: Series D (Nov 10, 2004)
- Investors on record: 14

## About

Alexza Pharmaceuticals, Inc. is focused on developing innovative therapeutic solutions that enhance patient care through advanced medication delivery systems.Founded in 2000 in Mountain View, US, Alexza Pharmaceuticals, Inc. specializes in the development of innovative drug delivery technologies for rapid absorption and targeted medication delivery. The company underwent a significant business pivot in 2006 when it raised USD 44 million in an IPO, selling 5.5 million shares at USD 8 per share. The company has completed 6 deals in total. Its focus remains on developing proprietary products aimed at improving treatment outcomes in various health conditions, with no known subsidiaries or parent companies.The company's core product offerings focus on innovative therapeutic solutions aimed at enhancing patient care in various medical conditions. These products are designed to address specific health challenges, leveraging advanced delivery systems to ensure efficacy and convenience for end users. The primary focus is on formulations that enable rapid absorption and targeted delivery of medications, which is particularly beneficial for patients requiring immediate relief or chronic management of their conditions. The company serves a diverse clientele, including healthcare providers, hospitals, and specialty pharmacies across North America and select international markets in Europe and Asia. By targeting both healthcare professionals and patients, the company aims to improve treatment outcomes and patient compliance through its user-friendly solutions.In the most recent year of 2015, the company generated revenue of USD 5.56 mn. For the same year, it reported an EBITDA of USD -31.68 mn, highlighting the financial challenges faced while developing its product portfolio.Alexza Pharmaceuticals plans to utilize its recent funding to advance the development of new products that promise to enhance medication delivery efficacy. The company is targeting expansion into European and Asian markets by 2025, focusing on establishing partnerships with local healthcare providers. The recent PIPE funding of USD 3.00 mn will be allocated to support these initiatives, including R&D for upcoming product launches aimed at addressing acute and chronic health conditions.

## Funding rounds

- Series D, Nov 10, 2004, $47M — Abingworth, Alloy Ventures, Burrill & Company, Delphi Ventures, Frazier Healthcare Partners, New Enterprise Associates, T Rowe Price, Versant Ventures, Zesiger Capital Group, Presidio Partners, 5AM Ventures, West River Group, Pacific Rim Ventures, Lumira Ventures
- Series A, Sep 23, 2002, $45M — Alloy Ventures, Burrill & Company, Frazier Healthcare Partners, New Enterprise Associates, Versant Ventures, Zesiger Capital Group, Presidio Partners

## Investors

- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series A, Series D
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series D
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series D
- Zesiger Capital Group (https://capitalatlas.ai/funds/zesiger-capital-group) — Series A, Series D
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A, Series D
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series D
- West River Group — Series D
- Pacific Rim Ventures (https://capitalatlas.ai/funds/pacific-rim-ventures) — Series D
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series D